GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Theravance Biopharma
Theravance Biopharma is a biopharmaceutical company focused on developing treatments for inflammatory and respiratory diseases. Its share price is dependent on clinical trial success and royalties from its partner, YUPELRI.
Share prices of companies in the market segment - Pharma other
Theravance Biopharma is a biopharmaceutical company developing drugs for the treatment of respiratory and other diseases. We classified it in "Other Pharma" due to its diversified portfolio. The chart below reflects general trends in the biotech sector.
Broad Market Index - GURU.Markets
Theravance Biopharma is a biopharmaceutical company developing drugs for the treatment of respiratory and other diseases. Its diversified portfolio makes it a component of the GURU.Markets index. The chart below compares its price history with the overall market.
Change in the price of a company, segment, and market as a whole per day
TBPH - Daily change in the company's share price Theravance Biopharma
The daily price change of Theravance, a biopharmaceutical company, reflects the progress of its drug development. Change_co measures the high volatility associated with research results and partnerships. This metric is important for analyzing companies whose businesses rely on royalties and R&D on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma other
Theravance Biopharma, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparing it to TBPH, with its diversified development portfolio, helps understand how this impacts its risks.
Daily change in the price of a broad market stock, index - GURU.Markets
Theravance is a biopharmaceutical company specializing in drugs for the treatment of respiratory diseases. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing Theravance's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Theravance Biopharma
Theravance is a biopharmaceutical company. Its year-over-year performance reflects both the commercial success of its existing drugs and investor confidence in its R&D platform, which is focused on new breakthrough drugs.
Annual dynamics of market capitalization of the market segment - Pharma other
Theravance Biopharma, Inc. is a biopharmaceutical company that owns a portfolio of royalties and develops new drugs. Its complex structure and reliance on R&D success make it a unique player. The chart shows how the market values its diverse assets and its ability to commercialize its developments.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Theravance Biopharma is a biopharmaceutical company whose stock performance is driven by the sales success of its drugs and progress in research. The company's business is not dependent on economic cycles. The chart reflects biotech events rather than macroeconomic data, making it a non-cyclical growth story.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Theravance Biopharma
Domo, a provider of a cloud-based business intelligence (BI) platform, shows its monthly fluctuations, reflecting its ability to compete with giants like Microsoft Power BI and Tableau. Demand from companies for data visualization and analysis tools is also a key factor.
Monthly dynamics of market capitalization of the market segment - Pharma other
Theravance Biopharma develops drugs for the treatment of respiratory and inflammatory diseases. The biopharmaceutical sector is generally very sensitive to clinical trial results and partnerships. The chart below shows how investor sentiment has changed for companies working in these therapeutic areas.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Theravance Biopharma is a biopharmaceutical company that receives royalties from drugs sold by partners and develops its own. This hybrid model provides some stability. Share price performance reflects both current royalty income and investor confidence in the company's future drugs.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Theravance Biopharma
Theravance Biopharma is a biopharmaceutical company with a diversified portfolio. Weekly stock performance is driven by news about various research programs and royalties from partners, which can smooth out volatility compared to companies with a single product.
Weekly dynamics of market capitalization of the market segment - Pharma other
Theravance Biopharma is a biopharmaceutical company with a diversified portfolio. Comparing its weekly performance to the biotech index will reveal how the market views its model. The chart also shows whether royalty income provides greater stability than that of companies dependent on a single drug.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Shares of Theravance, a biotech company, can live in a world of their own. Their performance is often driven by product news and clinical data. A chart comparing the stock to the S&P 500 clearly demonstrates how the stock can move regardless of the broader market.
Market capitalization of the company, segment and market as a whole
TBPH - Market capitalization of the company Theravance Biopharma
The Theravance Biopharma market capitalization chart tells the story of drug development and intellectual property monetization. The company's performance reflects both its own clinical programs and the flow of royalties from successful drugs developed in partnership with other companies. It's a visualization of the hybrid model in biotechnology.
TBPH - Share of the company's market capitalization Theravance Biopharma within the market segment - Pharma other
Theravance Biopharma is a biopharmaceutical company focused on the development and commercialization of drugs for the treatment of respiratory and inflammatory diseases. Its market share reflects the value of its commercial products and research pipeline. The chart below shows its market share in the drug market.
Market capitalization of the market segment - Pharma other
Theravance Biopharma focuses on the development and commercialization of drugs for the treatment of respiratory and other diseases. The chart below shows the overall market capitalization of the pharmaceutical sector. It helps assess the scale of the market in which the company competes and the potential value of its development pipeline.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Theravance Biopharma line on this chart is a story about the monetization of scientific research. The company develops drugs and then receives royalties from their sales to major partners. Its market capitalization is an estimate of the future cash flows from these licensing agreements. This is the "lab outsourcing" business model.
Book value capitalization of the company, segment and market as a whole
TBPH - Book value capitalization of the company Theravance Biopharma
Theravance Biopharma's book value is determined by its portfolio of approved and developing drugs, particularly in respiratory diseases, and its financial reserves. This represents its scientific and commercial capital. The chart shows how the company manages this capital, receiving royalties from partners and investing in its own R&D projects.
TBPH - Share of the company's book capitalization Theravance Biopharma within the market segment - Pharma other
Theravance Biopharma is a biopharmaceutical company focused on developing drugs for the treatment of respiratory and inflammatory diseases. Its assets are R&D laboratories. The chart shows a modest share of physical assets, as the company focuses on research rather than mass production.
Market segment balance sheet capitalization - Pharma other
Developing inhaled drugs like Theravance's is moderately capital-intensive. Compared to the pharmaceutical sector's assets, R&D makes it "easy," but manufacturing and commercialization require significant investment in physical assets.
Book value of all companies included in the broad market index - GURU.Markets
Theravance Biopharma's book value is not derived from its plants, but from its development pipeline and royalties from commercialized drugs, primarily for the treatment of respiratory diseases. The company's assets reflect both its scientific potential and its existing intellectual property. The chart illustrates its scale within the pharmaceutical industry.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Theravance Biopharma
Theravance Biopharma, which owns a portfolio of drugs and royalties, often trades below its book value. This may reflect investor concerns about patent expirations or the prospects for its new developments, despite its existing cash flows.
Market to book capitalization ratio in a market segment - Pharma other
Theravance Biopharma develops drugs to treat respiratory and other diseases. Its score on this chart is the sum of the scores for its commercial products and the potential of its clinical-stage development pipeline.
Market to book capitalization ratio for the market as a whole
Theravance Biopharma is a company developing drugs for the treatment of respiratory and inflammatory diseases. Its model often includes partnerships with large pharmaceutical companies. This metric reflects how investors assess its pipeline and its ability to commercialize them independently or through beneficial partnerships.
Debts of the company, segment and market as a whole
TBPH - Company debts Theravance Biopharma
Theravance Biopharma uses debt financing to support its diverse clinical programs. For a company with several products in development but limited revenue, debt and cash management are key to bringing the most promising candidates to market. This chart reflects its financial strategy for survival and growth.
Market segment debts - Pharma other
Theravance Biopharma is a biopharmaceutical company focused on developing drugs for the treatment of respiratory and inflammatory diseases. The company has both commercial products and a pipeline of developments. This chart shows how it balances royalty income with the need to fund expensive research to create new drugs.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Theravance Biopharma
Theravance Biopharma develops and commercializes drugs to treat respiratory and other diseases. The long journey from laboratory to pharmacy requires significant financing. This chart shows how the company uses debt to support its R&D programs and clinical trials, reflecting its financial risk while awaiting approval of new drugs.
Market segment debt to market segment book capitalization - Pharma other
Theravance Biopharma develops and commercializes drugs for the treatment of respiratory and other diseases. Its financial model often includes partnerships and royalties. This chart shows how the company manages its debt during the product launch process, relating it to the market capitalization of the entire pharmaceutical sector.
Debt to book value of all companies in the market
Theravance Biopharma develops drugs in various therapeutic areas. Its diversified research portfolio requires ongoing funding. Does the company raise debt to support its numerous programs? This graph of total debt in the economy allows us to assess its financial strategy and dependence on external capital.
P/E of the company, segment and market as a whole
P/E - Theravance Biopharma
Theravance Biopharma is a biopharmaceutical company developing drugs to treat respiratory and inflammatory diseases. This chart shows how investors view its pipeline and its ability to commercialize them. The valuation is volatile and dependent on clinical trial news.
P/E of the market segment - Pharma other
Theravance Biopharma is a biopharmaceutical company focused on developing and commercializing new drugs for the treatment of respiratory and other diseases. This chart shows the average valuation for the pharmaceutical sector, allowing investors to evaluate the company's scientific pipeline and commercial prospects.
P/E of the market as a whole
Theravance Biopharma focuses on developing drugs to treat respiratory and inflammatory diseases. The company has both commercial products and clinical development pipelines. Does its valuation reflect stable revenue from existing drugs or a risky bet on future breakthroughs? This chart helps understand how the market weighs these two factors.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Theravance Biopharma
Theravance Biopharma is a biopharmaceutical company focused on developing and commercializing drugs for the treatment of respiratory and other diseases. This chart reflects analysts' expectations for future revenue, which depend on successful sales of existing products and progress in clinical trials of new drug candidates.
%20P%2FE%20Theravance%20Biopharma&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Theravance-Biopharma&v=1772648234764 "Chart of the company's future (projected) P/E Theravance Biopharma")
Future (projected) P/E of the market segment - Pharma other
Theravance Biopharma is a biopharmaceutical company focused on the discovery and development of drugs for the treatment of respiratory and inflammatory diseases. The company has both commercial products and a pipeline of developments. The chart shows industry forecasts, allowing one to assess how the market balances Theravance's current revenues with the risks and potential of its R&D.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-other&v=1772648234770 "Future (projected) P/E graph of the market segment - Pharma other")
Future (projected) P/E of the market as a whole
Theravance Biopharma, Inc. develops and commercializes drugs in various therapeutic areas. The company's valuation depends on the success of its drug portfolio. This market sentiment graph is important because it influences how investors evaluate future cash flows from drug sales and the potential of its development pipeline.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772648234779 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Theravance Biopharma
Theravance Biopharma focuses on developing and commercializing drugs for the treatment of respiratory and inflammatory diseases. The company's financial results are a combination of royalty income from approved drugs and R&D expenses for new ones. This chart illustrates the complex balance between current revenue and investments in the future.
Profit of companies in the market segment - Pharma other
Theravance Biopharma focuses on developing and commercializing drugs for the treatment of respiratory and other diseases. This chart, which reflects the overall financial health of the pharmaceutical sector, illustrates the environment in which they operate. While their existing commercialized products provide them with stable revenue, their future growth depends on the success of new developments in their clinical pipeline.
Overall market profit
Theravance Biopharma develops drugs for the treatment of respiratory and inflammatory diseases. Like many biotech companies, the company relies on successful clinical trials and partnerships with major pharmaceutical companies. The overall economic situation, reflected in the chart, influences the willingness of large companies to enter into licensing deals and invest in the developments of players like Theravance.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Theravance Biopharma
Theravance Biopharma is a biopharmaceutical company focused on developing and commercializing drugs for the treatment of respiratory and inflammatory diseases. Its business model combines proprietary development with royalty-based revenue generation. This chart shows analysts' forecasts for sales of existing products and the success of future developments.
%20profit%20of%20the%20company%20Theravance%20Biopharma&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Theravance-Biopharma&v=1772648234807 "Graph of future (projected) profit of the company Theravance Biopharma")
Future (predicted) profit of companies in the market segment - Pharma other
Theravance Biopharma is a biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of respiratory diseases and other conditions. Its revenues consist of royalties and potential future sales. This pharmaceutical sector chart provides a general context for industry profitability, while Theravance's success depends on its specific product portfolio.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-other&v=1772648234811 "Graph of future (predicted) profits of companies in a market segment - Pharma other")
Future (predicted) profit of the market as a whole
Theravance Biopharma is a company developing drugs across various therapeutic areas. While its primary driver is science, its financial success depends on partnerships and licensing agreements with major pharmaceutical companies. The overall profit forecast, reflected in the chart, influences the budgets of these giants and their willingness to invest in R&D.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772648234904 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Theravance Biopharma
Theravance Biopharma is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic drugs. This chart shows how the market values its diversified revenues, which can include royalties and sales of its own products. It reflects investor assessments of both current revenues and the potential for future developments.
P/S market segment - Pharma other
Theravance Biopharma focuses on the development and commercialization of drugs for the treatment of respiratory and inflammatory diseases. The company's revenue consists of royalties and potential future sales. This chart, which reflects the average valuation in the pharmaceutical industry, helps understand the market's perception of Theravance's pipeline and commercial prospects.
P/S of the market as a whole
Theravance Biopharma is a biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of respiratory diseases and other conditions. This market revenue estimate chart serves as a proxy for expectations for Theravance. It demonstrates the value investors place on the company's pipeline in anticipation of future commercial success.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Theravance Biopharma
Theravance Biopharma is a biopharmaceutical company that develops drugs and receives royalties from commercialized products. Its business has two revenue streams. This chart reflects investors' combined expectations for both future royalties and the success of drugs in development, making valuation multifaceted.
%20P%2FS%20Theravance%20Biopharma&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Theravance-Biopharma&v=1772648235030 "The graph of the company's future (projected) P/S Theravance Biopharma")
Future (projected) P/S of the market segment - Pharma other
Theravance Biopharma is a biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of respiratory and other diseases. The company has a diversified pipeline. This chart reflects average future revenue expectations in the pharmaceutical sector, allowing for a comparison of how the market perceives Theravance's potential.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20other&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-other&v=1772648235038 "Future (projected) P/S market segment graph - Pharma other")
Future (projected) P/S of the market as a whole
Theravance Biopharma focuses on developing and commercializing drugs for the treatment of respiratory and inflammatory diseases. This chart shows overall market revenue forecasts. The company's success depends on regulatory approval of its new drugs and their ability to compete in the market. This reflects investor confidence in the potential of pharmaceutical innovation.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772648235047 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Theravance Biopharma
This chart shows the revenue of Theravance Biopharma, a company focused on the discovery, development, and commercialization of pharmaceuticals. Its revenue is generated through royalties from partners' already-marketed products and from its own sales. The dynamics reflect the commercial success of its drug portfolio, particularly in the field of respiratory diseases.
Sales of companies in the market segment - Pharma other
Theravance Biopharma is a biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of respiratory and other diseases. This chart illustrates the dynamics of the pharmaceutical market. The company's portfolio, which includes both commercial products and promising developments, allows it to influence the standard of care in its therapeutic area.
Overall market sales
Theravance Biopharma develops drugs in various therapeutic areas. Like many biotech companies, it relies on successful research and partnerships. The overall economic climate, reflected in this chart, influences the investment climate and funding of the healthcare sector.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Theravance Biopharma
Theravance Biopharma develops drugs to treat respiratory and inflammatory diseases. The company's future revenue depends on the commercial success of its products and royalties from partners. This chart shows analyst sales expectations for the company's current and future drugs.
%20sales%20of%20the%20company%20Theravance%20Biopharma&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Theravance-Biopharma&v=1772648235079 "Schedule of future (projected) sales of the company Theravance Biopharma")
Future (projected) sales of companies in the market segment - Pharma other
Theravance Biopharma specializes in the development and commercialization of drugs for the treatment of respiratory and inflammatory diseases. The company has a portfolio of both commercialized products and promising candidates. This chart shows the outlook for the pharmaceutical market, where respiratory diseases remain a key area with high demand.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-other&v=1772648235092 "Schedule of future (projected) sales of companies in the market segment - Pharma other")
Future (projected) sales of the market as a whole
Theravance Biopharma develops drugs to treat respiratory and inflammatory diseases. Its success depends on clinical trial results and partnerships with major pharmaceutical companies. This chart reflects the overall economic backdrop, but for Theravance, scientific data and strategic decisions that could lead to the creation of a new blockbuster are more important.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772648235098 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Theravance Biopharma
Theravance Biopharma focuses on developing and commercializing drugs for the treatment of respiratory and inflammatory diseases. Its financial performance reflects the complex balance between royalties from approved drugs and the enormous costs of researching new molecules. This chart shows the company's path from R&D to potential commercial viability.
Market segment marginality - Pharma other
Theravance Biopharma is a biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of respiratory and other diseases. Profitability depends on the success of its clinical programs and royalties from partners. This chart shows financial performance. Comparisons with other pharmaceutical companies highlight their strategy and product portfolio.
Market marginality as a whole
Theravance Biopharma is a biopharmaceutical company developing drugs in various therapeutic areas, often through partnerships with major pharmaceutical companies. Their model involves receiving royalties from approved drugs. This overall profitability curve is less important to them than the success of their R&D pipeline and the commercial performance of their partners.
Employees in the company, segment and market as a whole
Number of employees in the company Theravance Biopharma
Theravance Biopharma is a biopharmaceutical company with a diverse development portfolio. The size of its team, particularly in R&D, fluctuates depending on the stage of its clinical programs. This chart will reflect the company's investment cycles in R&D, which are the foundation of its business.
Share of the company's employees Theravance Biopharma within the market segment - Pharma other
Theravance Biopharma focuses on the development and commercialization of drugs for the treatment of respiratory and other diseases. This chart reflects the company's human resources footprint in its pharmaceutical niche. It is an indicator of the scale of its research programs, as the development of each new drug requires years of work by a large team of scientists, physicians, and researchers.
Number of employees in the market segment - Pharma other
Theravance Biopharma is a diversified biopharmaceutical company focused on developing drugs to treat respiratory diseases and other serious conditions. This chart reflects the dynamics of employment in the R&D sector. Fluctuations in scientific personnel are often driven by clinical trial results, partnerships with large pharmaceutical companies, and strategic decisions about research focus.
Number of employees in the market as a whole
Theravance Biopharma is a biopharmaceutical company focused on developing and commercializing drugs for the treatment of respiratory and other diseases. Its business model often includes partnerships with large pharmaceutical companies. This chart shows how innovative mid-sized pharmaceutical companies contribute to the overall healthcare ecosystem and drive employment.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Theravance Biopharma (TBPH)
Theravance Biopharma is a biotechnology company focused on developing drugs for the treatment of respiratory and other diseases. This chart reflects the value of its intellectual capital. The company's value is largely based on its developments and royalties from partners. The chart shows the market valuation of this IP and development portfolio per employee.
%20of%20the%20company%20Theravance%20Biopharma%20(TBPH)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Theravance-Biopharma-TBPH&v=1772648235167 "Chart of market capitalization per employee (in thousands of dollars) of the company Theravance Biopharma (TBPH)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma other
Theravance Biopharma develops and commercializes drugs in various therapeutic areas. Its value depends on the success of its R&D programs and partnerships. This chart shows how investors evaluate the company's scientific potential and development pipeline, with intellectual property being the primary value driver.
%20by%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-other&v=1772648235183 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma other")
Market capitalization per employee (in thousands of dollars) for the overall market
Theravance Biopharma is a biopharmaceutical company developing and commercializing drugs for the treatment of respiratory and other diseases. The chart shows the valuation of a company with a complex structure, including both commercial products and research programs. It reflects the total value of its assets per employee.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772648235192 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Theravance Biopharma (TBPH)
Theravance Biopharma is a biotech company with a hybrid model. They receive royalties from GSK for their COPD drug (Relvar/Breo) and also spend money on developing their own drugs. This chart illustrates this balance: stable royalty income generated by a small staff partially offsets the costs of R&D personnel.
%20Chart%20Theravance%20Biopharma%20(TBPH)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Theravance-Biopharma-TBPH&v=1772648235194 "Company Profit Per Employee (in thousands of dollars) Chart Theravance Biopharma (TBPH)")
Profit per employee (in thousands of dollars) in the market segment - Pharma other
Theravance Biopharma (TBPH) is a biopharmaceutical company that earns royalties from GSK for asthma/COPD medications while simultaneously developing its own new drugs. This figure reflects a hybrid model: stable royalty income and high R&D expenditures.
%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-other&v=1772648235195 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma other")
Profit per employee (in thousands of dollars) for the market as a whole
Theravance Biopharma (TBPH) is a biopharmaceutical company that receives royalties from GSK (for a lung drug) and conducts R&D in other areas. This chart shows how stable royalties cover (or don't cover) R&D costs (loss per employee). It's a balance between past success and new developments.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772648235195 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Theravance Biopharma (TBPH)
Theravance Biopharma develops and commercializes drugs for the treatment of respiratory and other diseases. This chart shows the financial return on its pipeline of drugs and developments. Growth in this indicator reflects increased sales of existing products or receipt of payments from partners for clinical trial successes.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Theravance-Biopharma-TBPH&v=1772648235198 "Sales chart per company employee Theravance Biopharma (TBPH)")
Sales per employee in the market segment - Pharma other
Theravance Biopharma focuses on developing drugs to treat respiratory and inflammatory diseases. This chart shows how productive their team of scientists and commercial specialists is. It measures revenue per employee, allowing them to compare their performance to other specialized pharmaceutical companies.
Sales per employee for the market as a whole
Theravance Biopharma (TBPH) focuses on developing drugs for the treatment of respiratory and inflammatory diseases. The company has both commercial products (which generate royalties) and R&D projects. This chart illustrates the hybrid model: how effectively royalties from past successes and the work of its current R&D staff combine to generate the company's total revenue.
Short shares by company, segment and market as a whole
Shares shorted by company Theravance Biopharma (TBPH)
Theravance Biopharma is a company focused on developing drugs for the treatment of respiratory and inflammatory diseases. The company has a complicated history with asset splits. This chart highlights the bearish bets of investors who may be disappointed with its pipeline and doubt its ability to bring new successful drugs to market.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Theravance-Biopharma-TBPH&v=1772648235522 "Short Shares Chart for the Company Theravance Biopharma (TBPH)")
Shares shorted by market segment - Pharma other
Theravance Biopharma is a biotech company that earns royalties from GSK (for a lung drug) and is trying to develop new drugs. This chart shows short bets. "Shorts" here are betting that their pipeline is empty and the royalty flow will soon dry up.
Shares shorted by the overall market
Theravance Biopharma specializes in drugs for respiratory diseases. The company has both commercial products and developmental pipelines. When fear rises on this chart, investors evaluate the balance sheet. Stable royalty income can provide a cushion, but R&D risks drag down the stock along with overall pessimism.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Theravance Biopharma (TBPH)
Theravance Biopharma (TBPH) is a biopharmaceutical company developing drugs for the treatment of respiratory and inflammatory diseases. Their business model also includes royalties from GSK. This chart measures momentum. It shows "overbought" (above 70) on news of trial success or "oversold" (below 30) amid R&D setbacks or patent disputes.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Theravance-Biopharma-TBPH&v=1772648235588 "RSI 14 indicator chart for the company's stock Theravance Biopharma (TBPH)")
RSI 14 Market Segment - Pharma other
Theravance (TBPH) is a biotech company developing drugs to treat inflammatory and respiratory diseases. The RSI_14_Seg for their biotech segment shows the overall sentiment. The chart helps us understand: is TBPH's volatility a reaction to their clinical trials, or is the entire biotech sector overheated (or oversold)?
RSI 14 for the overall market
Theravance Biopharma (TBPH) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic poses the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast TBPH (Theravance Biopharma)
Theravance Biopharma (TBPH) is a biopharmaceutical company that receives royalties from GSK for its COPD drug, Trelegy. The company uses these funds to develop new drugs. This chart shows the average analyst forecast. Their target prices are based on the stability of these royalties and the evaluation of their clinical programs.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-TBPH-Theravance-Biopharma&v=1772648235631 "A chart showing analyst consensus forecasts for the expected stock price. TBPH (Theravance Biopharma)")
The difference between the consensus estimate and the actual stock price TBPH (Theravance Biopharma)
Theravance Biopharma (TBPH) is a biopharmaceutical company specializing in respiratory diseases that receives royalties from GSK for its drug Trelegy. This chart shows their R&D valuation. It measures the gap between the price and the consensus target, reflecting whether analysts believe their pipeline can replace these royalties in the future.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-TBPH-Theravance-Biopharma&v=1772648235648 "A chart showing the difference between the consensus forecast and the actual stock price. TBPH (Theravance Biopharma)")
Analyst consensus forecast for stock prices by market segment - Pharma other
Theravance Biopharma (TBPH) is a respiratory disease company whose primary asset is royalties from YUPELRI, sold by Viatris. This chart shows analysts' overall expectations for the pharmaceutical sector. It reflects their confidence in the drug's commercial potential and the company's R&D pipeline.
Analysts' consensus forecast for the overall market share price
Theravance Biopharma (TBPH) is a biopharmaceutical company focused on developing drugs for the treatment of respiratory and inflammatory diseases. Their model is R&D and royalty payments. This chart shows the overall risk appetite in the market, reflecting the willingness of investors to invest in companies in the long-term clinical development phase.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Theravance Biopharma
Theravance Biopharma (TBPH) is a royalty-based biopharmaceutical company. Their main asset is a stake in a lung drug (Trelegy) sold by GSK. This chart is a barometer of their royalties. It likely reflects Trelegy's sales growth rate (which generates their cash) and the market's confidence in their early-stage R&D pipeline.
AKIMA Market Segment Index - Pharma other
Theravance (TBPH) is a biotech incubator focused on inflammatory diseases; the company owns a portfolio of royalties (on GSK asthma drugs) and is developing new drugs. This summary metric measures R&D. The graph shows the segment average. This benchmark: how does this hybrid (royalty + R&D) model (TBPH) differentiate it from the average pharma company?
The AKIM Index for the overall market
Theravance Biopharma is a biopharmaceutical company focused on respiratory diseases. It receives royalties from GSK (Trelegy) and sells Yupelri. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this company, which strives for profitability and capital return, compares to overall economic trends.
